Search Follow us

tv

1 - 12 of 251
Sort by: popularity | newest
Page  2 3 4 5 6 7 8 9 10  11>>  of 21 | Next
Toscafund Asset Management

Executive interview – Toscafund Asset Management

Edison TV: | Investment Companies | 16 Oct 2018

Dr Savvas Savouri, chief economist at Toscafund, discusses issues affecting the current macro-economic climate including Brexit, China and president Trump. Toscafund Asset Management LLP, founded in 2000 by Martin Hughes, is a multi-asset fund management firm with approximately $4bn of assets under management. Dr Savouri’s discussion papers can be found here.

WANdisco

Executive interview - WANdisco

Edison TV: | Technology | 01 Oct 2018

David Richards, CEO, provides an update on WANdisco’s progress with its partners, most notably with Microsoft and IBM. He also explains the company’s revenue model, and how the changing partnerships are expected to alter WANdisco’s growth profile. Erik Miller, CFO, goes on to explain how the company expects to deliver a significant ramp in bookings and revenues to meet consensus forecasts for the full year. He also details the cash costs over H1, and how he expects these to evolve over the second half. Finally, David provides an overview of WANdisco’s entry into the blockchain ecosystem and the problems that DConE seeks to address.

Hurricane Energy

Executive interview - Hurricane Energy

Edison TV: | Oil & Gas | 01 Oct 2018

Robert Trice, CEO of Hurricane Energy, discusses how the company has amassed over two billion barrels of oil equivalent in 2P reserves and 2C resources and is on track to deliver first oil from the Lancaster early production system (EPS) in H119. Robert describes Hurricane’s recent deal with Spirit Energy, which accelerates the de-risking of the company’s Rona Ridge asset base, both in terms of the Greater Warwick Area (GWA) resource and the ability to focus Lancaster EPS cash flows on fast-track appraisal of the Greater Lancaster Area (GLA) resource base. Lastly, he discusses the outlook for 2019 including upcoming exploration and appraisal activity.

Nuevolution

Bitesize briefing - Nuevolution

Edison TV: | Pharmaceutical & healthcare | 25 Sep 2018

Nuevolution is a Copenhagen-based biopharmaceutical company with a patent-protected drug discovery platform (Chemetics) that enables the selection of drugs for an array of tough-to-drug disease targets. In this video, healthcare analyst Dr Daniel Wilkinson presents an overview of Nuevolution, covering its technology, financial position, partnerships and the wider competitive landscape. Additionally he details Edison’s approach to valuing the company.

Genesis Energy

Executive interview - Genesis Energy

Edison TV: | Utilities | 24 Sep 2018

is an energy company involved in the generation of electricity, retailing and trading of energy, and the development and procurement of fuel sources. The company operates through four segments: customer experience, energy management, oil and gas, and corporate. The customer experience segment is engaged in supplying energy (electricity, gas and liquefied petroleum gas [LPG]) and related services to end-user customers. The energy management segment is engaged in generating and trading electricity and related products. It includes electricity sales to the wholesale electricity market, derivatives entered into to fix the price of electricity, and wholesale gas and coal sales. The oil and gas segment is engaged in the exploration, development, production and sale of gas, LPG and light oil. The corporate segment is engaged in new generation investigation and development, fuel management, information systems and property management, among others.

Regional REIT

Executive interview – Regional REIT

Edison TV: | Property | 20 Sep 2018

Regional REIT (RGL) provides shareholders with a highly diversified exposure to UK commercial property (predominantly office and industrial property) in the main regional centres of the UK, outside the M25 motorway. It aims to deliver an attractive total return to shareholders, of over 10% per annum in the long term, with a strong focus on income plus capital growth. In this interview, Stephen Inglis, Chief Executive Officer of London & Scottish Investments Limited, RGL’s asset manager, discusses the strong interim results that were recently announced, progress with strategy and future prospects.

Lighthouse Group

Executive interview – Lighthouse Group

Edison TV: | Financials | 04 Sep 2018

Lighthouse Group’s main focus is on providing financial advice to ‘Middle Britain’ and is differentiated by contracts with 21 affinity partners. In this interview CEO Malcolm Streatfield discusses the results for the first half of 2018, highlighting good overall progress with revenues up by 5% from H117, PBT 12% and earnings per share 13%. The interim dividend was increased by 67%. Malcolm also outlines the group’s dividend policy, progress in the affinity business, an increasing level of recurring income and a positive start to H218.

Boku

Executive interview – Boku

Edison TV: | Technology | 04 Sep 2018

Boku, the largest independent direct carrier billing (DCB) company, listed on AIM in November 2017. Boku operates a billing platform that connects digital content merchants with mobile network operators (MNOs) in more than 50 countries. Supporting merchants to offer DCB helps them to acquire customers and convert them to loyal, paying customers. Boku has signed up the leading merchants in key digital content categories (music, app stores, games) and, after a period of investment to connect merchants and MNOs to its platform, is seeing strong volume growth. Boku has c 150 employees, with its main offices in the US, UK, Germany and India.

EMIS Group

Executive interview – EMIS Group

Edison TV: | Technology | 31 Aug 2018

EMIS is a clinical software supplier to the UK healthcare market. The company was originally established to serve the GP market, where it has a dominant position with a market share of 56% of UK GP practices. It has expanded from this position to create a broad range of products serving the community, child and mental healthcare (CCMH) market, the acute sector, and community pharmacies (where it has c 37% share), as well specialist software and screening services for diabetic retinopathy. The company strategy is to provide connected healthcare solutions to facilitate patient-centric care.

VolitionRx

Executive interview – VolitionRx

Edison TV: | Pharmaceutical & healthcare | 20 Aug 2018

Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

APQ Global

Executive interview - APQ Global

Edison TV: | Financials | 16 Jul 2018

APQ is an international emerging markets company, which aims to deliver a stable and growing dividend and capital growth for its shareholders by focusing on income-generating business opportunities, with good value and long-term growth potential. In this interview, CEO Bart Turtelboom gives his views on a range of topics and the potential opportunities for APQ that these represent, including the recent volatility in emerging markets, the Turkish elections, Argentina, China-US relations, and local currency emerging market debt.

ASIT Biotech

Executive interview – ASIT Biotech

Edison TV: | Pharmaceutical & healthcare | 16 Jul 2018

ASIT Biotech is a Belgian biotechnology company focused on late-stage clinical development of allergy immunotherapies (AITs). Its first product in Phase III is a grass pollen AIT with the advantages of a very short administration. ASIT’s AITs require only four treatment visits in 3 weeks to the allergist prior to the pollen season rather than visits for most of the year which are needed with other subcutaneous AITs, or over many years for sublingual AITs. CEO, Thierry Legon, discusses the advantages of ASIT’s technology, its strong patent position and the timing for its next Phase III study, and the potential for ASIT’s technology platform to generate AITs in other allergy indications.